Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rhenium (188Re) bis(perthiobenzoato)(dithiobenzoato)rhenium(III)
- Development stage
- Unknown
- Lead developer
- Centre Eugene Marquis
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intra-arterial
01
Overview
[188Re]-bis(perthiobenzoato)(dithiobenzoato)rhenium (III), commonly referred to as 188Re-SSS, is an experimental lipophilic radiopharmaceutical developed by the Centre Eugène Marquis for the treatment of hepatocellular carcinoma (HCC). The complex consists of the beta-emitting radionuclide rhenium-188 coordinated with sulfur-containing ligands, specifically bis(perthiobenzoato) and dithiobenzoato groups. This chemical structure imparts high lipophilicity, allowing the drug to be dissolved in Lipiodol (ethiodized oil), a contrast agent that is selectively taken up and retained by hypervascular liver tumors. Administered via transarterial radioembolization (TARE), the 188Re-SSS/Lipiodol formulation delivers localized, high-energy beta radiation (2.1 MeV) directly to the tumor site, causing lethal DNA damage in malignant cells while minimizing exposure to healthy liver parenchyma. This approach is particularly investigated for patients with advanced HCC or those who are not candidates for surgical resection.
- Other names
- [188Re]-bis(perthiobenzoato)(dithiobenzoato)rhenium (III)188Re-SSS complexRhenium-188-SSSRhenium188-SSSRhenium 188-SSS
02
Targets
DNA
Beyond the preview
Go deeper on rhenium (188Re) bis(perthiobenzoato)(dithiobenzoato)rhenium(III).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rhenium (188Re) bis(perthiobenzoato)(dithiobenzoato)rhenium(III).